ravulizumab

16th Sep 2025

Plain language summary: Global Registry data shows patients with aHUS can safely and effectively change from eculizumab to ravulizumab treatment

This Plain Language Summary of Publication from Future Rare Diseases describes the results from two ongoing study which looks at two approved treatments for a rare blood disease called nocturnal hemoglobinuria (PNH). The two treatments which under investigation in this study are called Eculizumab and ravulizumab. This article describes the results at 2 years for both studies.

22nd May 2023

Plain Language Summary: Is ravulizumab a suitable long-term treatment option for patients with paroxysmal nocturnal hemoglobinuria?